Jiangsu Sihuan Bioengineering Co., Ltd
Status: Publicly traded
Direct answer
Jiangsu Sihuan Bioengineering Co., Ltd is publicly traded on SHZ under the ticker 000518.SZ.
Jiangsu Sihuan Bioengineering Co., Ltd. is a Chinese pharmaceutical company. Its product portfolio includes anti-cancer biotherapeutics such as Drewson, prescribed for renal cancer, malignant melanoma, and cancerous effusions in the chest and abdomen. Another significant oncology drug, Xinde Lusheng, targets a much wider spectrum of malignancies, including kidney, melanoma, lung, gastric, malignant lymphoma, breast,...
Can you invest in Jiangsu Sihuan Bioengineering Co., Ltd?
Yes. Jiangsu Sihuan Bioengineering Co., Ltd trades publicly on SHZ as 000518.SZ.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Jiangsu Sihuan Bioengineering Co., Ltd
Detailed equity research is provided by MarketSnap.